[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 17 of about 17
1. Zorzi M, Fedato C, Naldoni C, Sassatelli R, Sassoli De' Bianchi P, Senore C, Visioli CB, Cogo C: Screening for colorectal cancer in Italy: 2007 survey. Epidemiol Prev; 2009 May-Jun;33(3 Suppl 2):57-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the South of Italy and Islands only one new programme was activated in 2007, while two others were stopped, with a decline of theoretical extension from 10% to 7%.
  • Among the 914,029 subjects attending screening for the first time, the detection rate (DR) per 1,000 screened subjects was 2.7 for invasive cancer and 12.2 for advanced adenomas (AA, adenomas with a diameter >/=1 cm, with villous/tubulovillous type or with high-grade dysplasia).
  • The DR of cancer and adenomas increased with age and was higher among males; 25% of screen-detected cancers were in TNM stage III+.
  • Many programmes reported some difficulties in guaranteeing TC in the appropriate time frame to SOF+ subjects: in 23.9% of cases the waiting time was longer than two months.
  • [MeSH-major] Adenoma / diagnosis. Carcinoma / diagnosis. Colorectal Neoplasms / diagnosis. Mass Screening / statistics & numerical data

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19776487.001).
  • [ISSN] 1120-9763
  • [Journal-full-title] Epidemiologia e prevenzione
  • [ISO-abbreviation] Epidemiol Prev
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


2. Ortega Carnicer J, Ambrós Checa A, Diarte De Miguel J: [Acute pancreatitis, acute kidney failure, metformin intoxication and villous rectal adenoma]. Med Intensiva; 2006 Nov;30(8):409-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute pancreatitis, acute kidney failure, metformin intoxication and villous rectal adenoma].
  • [Transliterated title] Pancreatitis aguda, insuficiencia renal aguda, intoxicación por metformina y adenoma velloso rectal.

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • Hazardous Substances Data Bank. METFORMIN HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17129542.001).
  • [ISSN] 0210-5691
  • [Journal-full-title] Medicina intensiva
  • [ISO-abbreviation] Med Intensiva
  • [Language] SPA
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Hypoglycemic Agents; 9100L32L2N / Metformin
  •  go-up   go-down


3. Goldstein PJ, Cabanas J, da Silva RG, Sugarbaker PH: Pseudomyxoma peritonei arising from colonic polyps. Eur J Surg Oncol; 2006 Sep;32(7):764-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: Pseudomyxoma peritonei may have as its primary site a mucinous gastrointestinal adenoma or carcinoma that gains access to the peritoneal cavity.
  • This manuscript describes this disease arising from a benign or malignant colonic polyp.
  • The patients developed the characteristic pseudomyxoma peritonei syndrome.
  • All three patients were treated with cytoreductive surgery plus perioperative hyperthermic intraperitoneal chemotherapy.
  • If pseudomyxoma peritonei develops, cytoreductive surgery and perioperative intraperitoneal chemotherapy should be considered for treatment.
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adenoma, Villous / pathology. Adenoma, Villous / surgery. Adult. Aged. Female. Humans

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16765563.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


Advertisement
4. Farraye FA, Wallace M: Clinical significance of small polyps found during screening with flexible sigmoidoscopy. Gastrointest Endosc Clin N Am; 2002 Jan;12(1):41-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In deciding how to interpret the significance and management of small distal adenomatous polyps found on FS, one must first decide on the goal of a screening program.
  • Unfortunately cost and cost-effectiveness are important considerations when administering a screening program with a fixed budget.
  • Multiple studies support the recommendation that villous polyps regardless of size and adenomatous polyps greater than 1 cm found on FS are important markers for the presence of advanced polyps and cancer in the proximal colon.
  • If one assumes that a sigmoidoscopy-based approach is reasonable, and accepts that such an approach always misses a small number of proximal lesions, how should one manage patients with a small adenomatous polyp on FS?
  • In aggregate, the studies discussed previously suggest that patients with no distal polyps, distal hyperplastic polyps, or a single small distal tubular adenoma have a similar and low risk of advanced proximal adenomas of the colon.
  • The study by Read et al also included patients with distal villous adenomas in their low-risk group.
  • Given these caveats, what can one conclude about the predictive value of a small tubular adenoma found on FS?
  • These studies suggest that the risk of proximal advanced polyps is similar or slightly increased in patients with a distal adenoma than those with a negative FS.
  • The risk of finding an advanced adenoma seems to be 0% to 4% regardless of the findings of no polyps, hyperplastic polyps, or small tubular adenomatous polyps on FS in low-risk patients.
  • A small portion of patients with hyperplastic polyps found on FS have advanced proximal adenomas.
  • If a hyperplastic polyp on FS is not an indication for colonoscopy and the risk of proximal advanced adenomas is similar in patients with only a small distal adenoma, it is inconsistent to recommend colonoscopy for a small distal tubular adenoma and not a hyperplastic polyp.
  • Based on the studies of asymptomatic patients with no family history and negative FOBT, the authors believe it is reasonable to defer colonoscopy if no polyp, a hyperplastic, or a small tubular adenoma is found at sigmoidoscopy in low-risk patients.
  • It remains to be seen if the increase in costs and risks justifies the improved detection rate of colonic polyps.
  • Given manpower issues that face us today, and examining the question from a population perspective, reserving colonoscopy for only those patients with an advanced distal polyp on FS gives the biggest yield.

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11916160.001).
  • [ISSN] 1052-5157
  • [Journal-full-title] Gastrointestinal endoscopy clinics of North America
  • [ISO-abbreviation] Gastrointest. Endosc. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 45
  •  go-up   go-down


5. Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransohoff DF: Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. N Engl J Med; 2000 Jul 20;343(3):169-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings.
  • BACKGROUND AND METHODS: The clinical significance of a distal colorectal polyp is uncertain.
  • We determined the risk of advanced proximal neoplasia, defined as a polyp with villous features, a polyp with high-grade dysplasia, or cancer, among persons with distal hyperplastic or neoplastic polyps as compared with the risk among persons with no distal polyps.
  • We analyzed data from 1994 consecutive asymptomatic adults (age, 50 years or older) who underwent colonoscopic screening for the first time between September 1995 and December 1998 as part of a program sponsored by an employer.
  • RESULTS: Sixty-one patients (3.1 percent) had advanced lesions in the distal colon, including 5 with cancer, and 50 (2.5 percent) had advanced proximal lesions, including 7 with cancer.
  • Twenty-three patients with advanced proximal neoplasms (46 percent) had no distal polyps.
  • The prevalence of advanced proximal neoplasia among patients with no distal polyps was 1.5 percent (23 cases among 1564 persons; 95 percent confidence interval, 0.9 to 2.1 percent).
  • Among patients with distal hyperplastic polyps, those with distal tubular adenomas, and those with advanced distal polyps, the prevalence of advanced proximal neoplasia was 4.0 percent (8 cases among 201 patients), 7.1 percent (12 cases among 168 patients), and 11.5 percent (7 cases among 61 patients), respectively.
  • The relative risk of advanced proximal neoplasia, adjusted for age and sex, was 2.6 for patients with distal hyperplastic polyps, 4.0 for those with distal tubular adenomas, and 6.7 for those with advanced distal polyps, as compared with patients who had no distal polyps.
  • CONCLUSIONS: Asymptomatic persons 50 years of age or older who have polyps in the distal colon are more likely to have advanced proximal neoplasia than are persons without distal polyps.
  • However, if colonoscopic screening is performed only in persons with distal polyps, about half the cases of advanced proximal neoplasia will not be detected.
  • [MeSH-major] Adenoma / complications. Colonic Polyps / complications. Colorectal Neoplasms

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] N Engl J Med. 2000 Nov 30;343(22):1651; author reply 1652-4 [11184981.001]
  • [CommentIn] N Engl J Med. 2000 Nov 30;343(22):1652-4 [11184982.001]
  • [CommentIn] N Engl J Med. 2000 Nov 30;343(22):1651-2; author reply 1652-4 [11184980.001]
  • (PMID = 10900275.001).
  • [ISSN] 0028-4793
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / K24 DK02756-02
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  •  go-up   go-down


6. Lin OS, Schembre DB, McCormick SE, Gluck M, Patterson DJ, Jiranek GC, Soon MS, Kozarek RA: Risk of proximal colorectal neoplasia among asymptomatic patients with distal hyperplastic polyps. Am J Med; 2005 Oct;118(10):1113-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of proximal colorectal neoplasia among asymptomatic patients with distal hyperplastic polyps.
  • PURPOSE: Many guidelines on colorectal cancer screening do not consider distal hyperplastic polyps to be a marker for proximal neoplasia.
  • However, 11 of 17 published studies have shown an increased risk of proximal neoplasia in patients with distal hyperplastic polyps.
  • Our goal is to assess the risk of proximal neoplasia in asymptomatic patients with distal hyperplastic polyps, compared to those with distal tubular adenomas or no distal polyps.
  • METHODS: We assessed proximal (cecum, ascending, transverse colon and splenic flexure) and distal polyps in patients undergoing screening colonoscopy, classifying them into 3 groups: distal hyperplastic polyps only; distal adenomas with or without hyperplastic polyps; no distal polyps.
  • The prevalence of proximal neoplasia and advanced neoplasia (polyps > or =1 cm, villous adenomas, or cancer) was compared among these groups.
  • Proximal neoplasia occurred in 175 (9%) of 1896 patients with no distal polyps, compared with 28 (12%) of 237 with distal hyperplastic polyps (P = 0.20) and 64 (29%) of 224 with distal adenomas (P <0.0001).
  • Proximal advanced neoplasia occurred in 39 (2%) patients with no distal polyps, compared with 4 (2%) with distal hyperplastic polyps (P = 0.70) and 9 (4%) with distal adenomas (P = 0.13).
  • CONCLUSIONS: Patients with distal hyperplastic polyps, unlike those with distal adenomas, do not exhibit an increased risk for proximal neoplasia or proximal advanced neoplasia compared to those with no distal polyps.
  • [MeSH-major] Adenoma / epidemiology. Colon / pathology. Colorectal Neoplasms / epidemiology. Intestinal Polyps / epidemiology. Precancerous Conditions / epidemiology. Rectum / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16194642.001).
  • [ISSN] 0002-9343
  • [Journal-full-title] The American journal of medicine
  • [ISO-abbreviation] Am. J. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


7. Pinsky PF, Schoen RE, Weissfeld JL, Bresalier RS, Hayes RB, Gohagan JK: Predictors of advanced proximal neoplasia in persons with abnormal screening flexible sigmoidoscopy. Clin Gastroenterol Hepatol; 2003 Mar;1(2):103-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & AIMS: The relationship between distal and proximal colonic findings is uncertain.
  • METHODS: We analyzed data from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial to assess the relationship between distal and proximal colonic findings.
  • Subjects with <10-mm single or multiple tubular adenomas had similar risks for advanced proximal neoplasia as subjects with hyperplastic polyps or other benign lesions (3%-5%).
  • Subjects with large (>or=10 mm), villous, or severely dysplastic distal adenomas had similarly elevated risks for advanced proximal neoplasia (11%-12%).
  • Multivariate logistic modeling showed a significantly increased risk for advanced proximal neoplasia associated with the presence of a large tubular (odds ratio [OR], 2.6; 95% confidence interval [CI], 2.0-3.4) or villous distal adenoma (OR, 2.7; 95% CI, 2.1-3.5) but not with the presence of one (OR, 1.05; 95% CI, 0.8-1.3) or multiple (OR, 0.8; 95% CI, 0.5-1.2) <10-mm tubular distal adenomas.
  • CONCLUSIONS: Among subjects with a polypoid lesion on screening flexible sigmoidoscopy, those with small tubular distal adenomas are at similar risk for advanced proximal neoplasia as those without distal adenomas.
  • Subjects with a large, villous, or dysplastic distal adenoma are at increased risk.
  • A strategy that encourages individuals with small tubular adenomas on sigmoidoscopy to undergo follow-up colonoscopy and excludes those with nonadenomatous lesions is of questionable validity, because both groups are at similar risk for advanced proximal neoplasia.
  • [MeSH-major] Adenoma / diagnosis. Colonic Neoplasms / diagnosis. Colonoscopy. Sigmoidoscopy

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15017502.001).
  • [ISSN] 1542-3565
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Emrich J, Niemeyer C: [The secreting villous adenoma as a rare cause of acute renal failure]. Med Klin (Munich); 2002 Oct 15;97(10):619-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The secreting villous adenoma as a rare cause of acute renal failure].
  • [Transliterated title] Das sezernierende villöse Adenom als seltene Ursache einer akuten Niereninsuffizienz.
  • BACKGROUND: Using a typical case the symptomatology, the clinical course, the diagnostics with its difficulties as well as the therapy of the rare secreting villous adenoma with severe electrolyte and fluid depletion syndrome are described.
  • By an increase of the mucous volume together with an exhaustion of the physiological compensation mechanisms a life-threatening condition with severe electrolyte and fluid loss as well as acute prerenal failure develops, which can lead to difficulties in the diagnosis finding.
  • Therefore, especially in case of a triade of prerenal failure, electrolyte disorder and chronic diarrhea, the existence of an intestinal villous adenoma should be considered.
  • TREATMENT: After restoration of the homeostasis, the surgical removal of the infested intestine section should be the first aim, in order to eliminate the chronic electrolyte and fluid loss and detect or prevent a malignant degeneration.
  • Only in exempt cases an endoscopic treatment or a drug therapy with indometacin can alternatively be considered.
  • An untreated secreting villous adenoma on the other side shows a mortality of 100%.
  • [MeSH-major] Acute Kidney Injury / etiology. Adenoma, Villous / secretion. Colonic Neoplasms / secretion

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12386796.001).
  • [ISSN] 0723-5003
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


9. Reichart M, Busch OR, Bruno MJ, Van Lanschot JJ: Black esophagus: a view in the dark. Dis Esophagus; 2000;13(4):311-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 73-year-old man had a low anterior resection for a villous adenoma in the rectosigmoid.
  • On the 4th day after surgery, he suddenly developed severe interscapular pain.
  • With conservative treatment, including proton pump inhibition, he recovered completely.

  • MedlinePlus Health Information. consumer health - Esophagus Disorders.
  • Hazardous Substances Data Bank. SUCRALFATE .
  • Hazardous Substances Data Bank. OMEPRAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11284980.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Ulcer Agents; 0 / Proton Pump Inhibitors; 54182-58-0 / Sucralfate; KG60484QX9 / Omeprazole
  •  go-up   go-down


10. Franklin ME Jr, Díaz-E JA, Abrego D, Parra-Dávila E, Glass JL: Laparoscopic-assisted colonoscopic polypectomy: the Texas Endosurgery Institute experience. Dis Colon Rectum; 2000 Sep;43(9):1246-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: From May 1990 to September 1999 laparoscopic-monitored colonic polypectomies were performed in 47 patients, with a total of 60 polyps being removed.
  • If the pathologic evaluation indicates malignancy then a segmental resection may be performed, otherwise the patients are decompressed and fed within a short time before discharge.
  • The most common histopathologic diagnosis was tubulovillous adenoma in 28 polyps followed by villous adenoma in 11 polyps.
  • This less invasive procedure yields recovery times similar to that of colonoscopy alone, and the potential complications of a segmental resection are avoided.
  • [MeSH-minor] Acetaminophen / therapeutic use. Adenoma, Villous / surgery. Aged. Analgesics, Non-Narcotic / therapeutic use. Colonic Neoplasms / surgery. Female. Humans. Male. Pain, Postoperative / drug therapy

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • Hazardous Substances Data Bank. ACETAMINOPHEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11005491.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Analgesics, Non-Narcotic; 362O9ITL9D / Acetaminophen
  •  go-up   go-down


11. Cruz-Correa M, Hylind LM, Romans KE, Booker SV, Giardiello FM: Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology; 2002 Mar;122(3):641-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study.
  • Sulindac, a nonsteroidal anti-inflammatory drug, causes regression of colorectal adenomas in the retained rectal segment of FAP patients, although long-term use of this therapy has not been studied.
  • We evaluated the long-term effectiveness and toxicity of sulindac in attempting to maintain retained rectal segments free of adenomas.
  • Number, size, and histologic grade of polyps, side effects, and medication compliance were assessed every 4 months.
  • Prevention of recurrence of higher-grade adenomas (tubulovillous, villous adenomas) was also observed (P = 0.004).
  • At 35 months of follow-up, 1 patient developed stage III cancer in the rectal stump.
  • CONCLUSIONS: Long-term use of sulindac seems to be effective in reducing polyp number and preventing recurrence of higher-grade adenomas in the retained rectal segment of most FAP patients.
  • [MeSH-major] Adenomatous Polyposis Coli / drug therapy. Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Sulindac / administration & dosage
  • [MeSH-minor] Adult. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Prospective Studies. Rectum / pathology

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11874996.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 184SNS8VUH / Sulindac
  •  go-up   go-down


12. Smith J, Hwang H, Wiseman KW, Filipenko D, Phang PT: Ex vivo sentinel lymph node mapping in colon cancer: improving the accuracy of pathologic staging? Am J Surg; 2006 May;191(5):665-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: A subset of patients with colon cancer staged by conventional methods have occult micrometastases and do not receive adjuvant chemotherapy.
  • [MeSH-major] Adenoma, Villous / secondary. Colonic Neoplasms / pathology. Lymph Nodes / pathology

  • Hazardous Substances Data Bank. Isosulfan blue .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16647356.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Rosaniline Dyes; 39N9K8S2A4 / iso-sulfan blue
  •  go-up   go-down


13. Sun WL, Hutarew G, Gradl J, Gratzl M, Denz H, Fiegl M: Successful antiangiogenic combination therapy for pseudomyxoma peritonei with bevacizumab and capecitabine. Cancer Biol Ther; 2009 Aug;8(15):1459-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful antiangiogenic combination therapy for pseudomyxoma peritonei with bevacizumab and capecitabine.
  • Effective systemic therapy for advanced pseudomyxoma peritonei (PMP) is the focus of investigation.
  • We describe a case of PMP arising from an adenoma of the appendix in a 58-year-old man.
  • Subsequently, six cycles of Folfox IV chemotherapy were administered, without response, but with severe side effects.
  • Upon progressive disease, a combination of bevacizumab and capecitabine led to a long term stabilization of disease and obvious improvement of performance status.
  • [MeSH-major] Adenoma, Villous / secondary. Angiogenesis Inhibitors / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Appendiceal Neoplasms / complications. Peritoneal Neoplasms / secondary. Pseudomyxoma Peritonei / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Capecitabine. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease Progression. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Fluorouracil / analogs & derivatives. Hernia, Inguinal / complications. Hernia, Inguinal / surgery. Humans. Ileocecal Valve / surgery. Leucovorin / administration & dosage. Leucovorin / adverse effects. Male. Middle Aged. Organoplatinum Compounds / administration & dosage. Organoplatinum Compounds / adverse effects. Treatment Outcome

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19483475.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Organoplatinum Compounds; 0W860991D6 / Deoxycytidine; 2S9ZZM9Q9V / Bevacizumab; 6804DJ8Z9U / Capecitabine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


14. Kuratate S, Inoue S, Chikakiyo M, Kaneda Y, Harino Y, Hirose T, Yagi T, Saitoh S, Sumitomo M, Fujino R, Satake N: Coexistent poorly-differentiated neuroendocrine cell carcinoma and non-invasive well-differentiated adenocarcinoma in tubulovillous adenoma of the rectum: report of a case. J Med Invest; 2010 Aug;57(3-4):338-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistent poorly-differentiated neuroendocrine cell carcinoma and non-invasive well-differentiated adenocarcinoma in tubulovillous adenoma of the rectum: report of a case.
  • A 74-years old man was referred to our hospital for treatment of a rectal mass.
  • Colonoscopy revealed villous tumor covering all the lower rectal lumen.
  • Biopsy yielded a diagnosis of adenoma.
  • Histological and immuno- histochemical features showed coexistent poorly-differentiated small cell neuroendocrine cell (NEC) carcinoma and non-invasive well-differentiated adenocarcinoma in tubulovillous adenoma.
  • However the chemotherapy with FOLFOX and Bevacizumab was performed postoperatively, the patient died in cancer 3 months after surgery.
  • Rectal poorly-differentiated NEC carcinomas are thought to be a tumor with a high malignant potential.
  • They would be evaluated, and effective multimodal therapy for NEC carcinomas should be established.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Villous / pathology. Carcinoma, Neuroendocrine / pathology. Neoplasms, Multiple Primary / pathology. Rectal Neoplasms / pathology
  • [MeSH-minor] Aged. Humans. Liver Neoplasms / pathology. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Lymphatic Metastasis / pathology. Lymphatic Metastasis / radiography. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20847536.001).
  • [ISSN] 1349-6867
  • [Journal-full-title] The journal of medical investigation : JMI
  • [ISO-abbreviation] J. Med. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


15. Riojas MA, Guo M, Glöckner SC, Machida EO, Baylin SB, Ahuja N: Methylation-induced silencing of ASC/TMS1, a pro-apoptotic gene, is a late-stage event in colorectal cancer. Cancer Biol Ther; 2007 Nov;6(11):1710-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The methylation status of ASC/TMS1 was analyzed in a series of colorectal cancer (CRC) cell lines, adenomas and primary colorectal cancers and normal colorectal tissue samples using methylation-specific PCR (MSP).
  • RT-PCR showed absence of mRNA expression in these same cell lines, and expression was restored after treatment with the demethylating drug 5-aza-2'-deoxyazacytidine.
  • The two unmethylated cell lines showed ASC/TMS1 mRNA expression both before and after treatment with 5-aza-2'-deoxyazacytidine.
  • Methylation was seen in 20 of 115 (17%) of primary colorectal cancer specimens, but no methylation was seen in 30 colorectal adenomas and 11 normal colorectal tissue samples.
  • Methylation status of ASC/TMS1 was correlated with a series of clinicopathological variables using multivariate analysis.
  • Methylation of ASC/TMS1 was more common in right-sided tumors (p = 0.02), concordant with hMLH1 methylation (p = 0.03) and is a late stage event, occurring in 0 of 18 tubular adenomas, 0 of 12 villous adenomas, 2 of 44 (5%) Stage 1 cancers, 8 of 31 (26%) Stage 2 cancers, 8 of 21 (38%) Stage 3 cancers and 2 of 19 (11%) Stage 4 cancers.
  • Methylation of ASC/TMS1 appears to be a late-stage event in colorectal carcinogenesis associated with invasive carcinomas but not with normal colorectal tissue or colorectal adenomas.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17986858.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytoskeletal Proteins; 0 / PYCARD protein, human; 0 / RNA, Messenger; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


16. Half E, Bercovich D, Rozen P: Familial adenomatous polyposis. Orphanet J Rare Dis; 2009;4:22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Familial adenomatous polyposis (FAP) is characterized by the development of many tens to thousands of adenomas in the rectum and colon during the second decade of life.
  • Most patients are asymptomatic for years until the adenomas are large and numerous, and cause rectal bleeding or even anemia, or cancer develops.
  • A less aggressive variant of FAP, attenuated FAP (AFAP), is characterized by fewer colorectal adenomatous polyps (usually 10 to 100), later age of adenoma appearance and a lower cancer risk.
  • In a subset of individuals, a MUTYH mutation causes a recessively inherited polyposis condition, MUTYH-associated polyposis (MAP), which is characterized by a slightly increased risk of developing CRC and polyps/adenomas in both the upper and lower gastrointestinal tract.
  • Presymptomatic and prenatal (amniocentesis and chorionic villous sampling), and even preimplantation genetic testing is possible.
  • Patients with progressive tumors and unresectable disease may respond or stabilize with a combination of cytotoxic chemotherapy and surgery (when possible to perform).
  • Adjunctive therapy with celecoxib has been approved by the US Food and Drug Administration and the European Medicines Agency in patients with FAP.
  • Individuals with FAP carry a 100% risk of CRC; however, this risk is reduced significantly when patients enter a screening-treatment program.

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • SciCrunch. KEGG: Data: Disease Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Gastroenterol. 1993 Dec;17(4):343-7, discussion 347-8 [8308223.001]
  • [Cites] Hum Mutat. 1994;3(2):121-5 [8199592.001]
  • [Cites] Hum Genet. 1994 Nov;94(5):543-8 [7959691.001]
  • [Cites] N Engl J Med. 1995 Mar 30;332(13):839-47 [7661930.001]
  • [Cites] Ann Surg. 1995 Aug;222(2):120-7 [7639579.001]
  • [Cites] Am Fam Physician. 1995 Sep 15;52(4):1210 [7668210.001]
  • [Cites] Surgery. 1996 Jun;119(6):615-23 [8650601.001]
  • [Cites] Br J Surg. 1996 Jun;83(6):769-70 [8696735.001]
  • [Cites] Br J Surg. 1996 Jul;83(7):885-92 [8813770.001]
  • [Cites] J Med Genet. 1996 Jul;33(7):540-3 [8818937.001]
  • [Cites] Br J Surg. 1996 Nov;83(11):1578-80 [9014679.001]
  • [Cites] AJR Am J Roentgenol. 1997 Aug;169(2):465-72 [9242755.001]
  • [Cites] Ann Surg. 1997 Oct;226(4):514-9; discussion 519-21 [9351719.001]
  • [Cites] Arch Dis Child. 1997 Nov;77(5):431-5 [9487968.001]
  • [Cites] Am J Hum Genet. 1998 Mar;62(3):736-7 [9497250.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Apr;8(4 Pt 2):353-60 [10207640.001]
  • [Cites] Am J Hum Genet. 1999 Sep;65(3):902-9 [10441594.001]
  • [Cites] Nucleic Acids Res. 1999 Sep 15;27(18):3638-44 [10471731.001]
  • [Cites] Fam Cancer. 2006;5(3):213-20 [16998666.001]
  • [Cites] Fam Cancer. 2006;5(3):227-35 [16998668.001]
  • [Cites] Fam Cancer. 2006;5(3):241-60; discussion 261-2 [16998670.001]
  • [Cites] Fam Cancer. 2006;5(3):275-85; discussion 287-8 [16998673.001]
  • [Cites] Gastrointest Endosc. 2006 Oct;64(4):530-7 [16996344.001]
  • [Cites] Genet Med. 2006 Nov;8(11):697-703 [17108761.001]
  • [Cites] Reprod Biomed Online. 2006 Nov;13(5):707-11 [17169185.001]
  • [Cites] Mol Hum Reprod. 2007 Feb;13(2):95-101 [17114207.001]
  • [Cites] Am J Gastroenterol. 2007 Jun;102(6):1284-90 [17355417.001]
  • [Cites] Hum Mutat. 2007 Oct;28(10):985-92 [17486639.001]
  • [Cites] Genet Test. 2007 Fall;11(3):315-20 [17949294.001]
  • [Cites] Gastrointest Endosc. 2008 Jan;67(1):61-7 [18155426.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Feb;6(2):180-5 [18237868.001]
  • [Cites] Fam Cancer. 2008;7(1):27-39 [17999161.001]
  • [Cites] Gut. 2008 May;57(5):704-13 [18194984.001]
  • [Cites] Curr Protoc Hum Genet. 2006 Aug;Chapter 10:Unit 10.8 [18428386.001]
  • [Cites] Endoscopy. 2008 May;40(5):437-42 [18398783.001]
  • [Cites] Am J Surg. 2008 Jun;195(6):741-8 [18436175.001]
  • [Cites] Clin Chem. 2008 Jul;54(7):1132-40 [18487285.001]
  • [Cites] Pathol Res Pract. 2008;204(7):479-90 [18538487.001]
  • [Cites] Ann Surg Oncol. 2008 Sep;15(9):2439-50 [18612695.001]
  • [Cites] Eur J Cancer. 2008 Nov;44(16):2404-10 [18706807.001]
  • [Cites] Gastrointest Endosc. 2008 Nov;68(5):911-9 [18561922.001]
  • [Cites] Gastroenterology. 2008 Dec;135(6):2014-8 [19013464.001]
  • [Cites] J Pediatr. 1999 Sep;135(3):390-5 [10484811.001]
  • [Cites] Endoscopy. 1999 Aug;31(6):412-6 [10494676.001]
  • [Cites] Am J Hum Genet. 1955 Sep;7(3):236-63 [13258558.001]
  • [Cites] Dis Colon Rectum. 1959 Sep-Oct;2:465-8 [13839882.001]
  • [Cites] Genet Test. 2004 Winter;8(4):421-30 [15684875.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1092-102 [15713943.001]
  • [Cites] Am J Med Genet A. 2005 Apr 15;134A(2):212-4 [15690400.001]
  • [Cites] Gastroenterology. 2005 Apr;128(4):1077-80 [15825088.001]
  • [Cites] Am J Gastroenterol. 2005 Jul;100(7):1498-502 [15984971.001]
  • [Cites] Dis Colon Rectum. 2005 Aug;48(8):1528-34 [15906134.001]
  • [Cites] Biochem Soc Trans. 2005 Aug;33(Pt 4):679-83 [16042573.001]
  • [Cites] Am J Med Genet A. 2006 Feb 1;140(3):200-4 [16411234.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):312-4 [16492921.001]
  • [Cites] Br J Surg. 2006 Apr;93(4):407-17 [16511903.001]
  • [Cites] Int J Cancer. 2006 Aug 15;119(4):807-14 [16557584.001]
  • [Cites] Gut. 1999 Dec;45(6):829-33 [10562580.001]
  • [Cites] Nucleic Acids Res. 2000 Mar 15;28(6):1355-64 [10684930.001]
  • [Cites] J Clin Oncol. 2000 May;18(9):1967-79 [10784639.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] Dis Colon Rectum. 2000 Jul;43(7):893-8; discussion 898-902 [10910233.001]
  • [Cites] Am J Pathol. 2000 Sep;157(3):747-54 [10980114.001]
  • [Cites] Gastroenterology. 2000 Dec;119(6):1454-60 [11113066.001]
  • [Cites] Ann Surg. 2001 Mar;233(3):360-4 [11224623.001]
  • [Cites] Arch Ophthalmol. 2001 Apr;119(4):597-602 [11296028.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):121-5 [11316554.001]
  • [Cites] Gastroenterology. 2001 Jul;121(1):195-7 [11438508.001]
  • [Cites] J Wound Ostomy Continence Nurs. 2001 Jul;28(4):184-9 [11452254.001]
  • [Cites] Nat Genet. 2002 Feb;30(2):227-32 [11818965.001]
  • [Cites] Gastroenterology. 2002 Mar;122(3):641-5 [11874996.001]
  • [Cites] N Engl J Med. 2002 Apr 4;346(14):1054-9 [11932472.001]
  • [Cites] Gut. 2002 May;50(5):636-41 [11950808.001]
  • [Cites] J Gastrointest Surg. 2002 Jan-Feb;6(1):82-7 [11986022.001]
  • [Cites] Hum Mutat. 2002 Jun;19(6):664 [12007223.001]
  • [Cites] Gut. 2002 Sep;51(3):446-9 [12171972.001]
  • [Cites] J Clin Microbiol. 2002 Oct;40(10):3565-71 [12354847.001]
  • [Cites] Dis Colon Rectum. 2002 Nov;45(11):1496-502 [12432298.001]
  • [Cites] Br J Surg. 2003 Feb;90(2):227-31 [12555301.001]
  • [Cites] N Engl J Med. 2003 Feb 27;348(9):791-9 [12606733.001]
  • [Cites] Dis Colon Rectum. 2003 Apr;46(4):481-5 [12682541.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1752-5 [12702556.001]
  • [Cites] Gastroenterology. 2003 May;124(6):1574-94 [12761718.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):3891-3 [12873979.001]
  • [Cites] Dis Colon Rectum. 2003 Oct;46(10):1418-23; discussion 1422-3 [14530685.001]
  • [Cites] Fam Cancer. 2001;1(2):75-82 [14574001.001]
  • [Cites] Fam Cancer. 2003;2(1):43-55 [14574166.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4756-60 [14581346.001]
  • [Cites] Dig Dis Sci. 2003 Oct;48(10):1998-2002 [14627347.001]
  • [Cites] Genet Test. 2003 Fall;7(3):189-94 [14641994.001]
  • [Cites] Cancer. 2004 Feb 1;100(3):612-20 [14745880.001]
  • [Cites] Gut. 2004 Mar;53(3):381-6 [14960520.001]
  • [Cites] Hum Mutat. 2003 Jun;21(6):655-6 [14961559.001]
  • [Cites] Int J Cancer. 2004 May 1;109(5):680-4 [14999774.001]
  • [Cites] Oncogene. 2004 Sep 2;23(40):6820-2 [15273732.001]
  • [Cites] Gastroenterology. 2004 Sep;127(3):838-44 [15362039.001]
  • [Cites] Acta Chir Scand. 1975;141(3):228-37 [1166747.001]
  • [Cites] Am J Hum Genet. 1988 Feb;42(2):290-6 [3422541.001]
  • [Cites] Lancet. 1989 Sep 30;2(8666):783-5 [2571019.001]
  • [Cites] Ann Med. 1989 Aug;21(4):299-307 [2551351.001]
  • [Cites] Gastroenterology. 1991 Jun;100(6):1658-64 [1673441.001]
  • [Cites] Cell. 1991 Aug 9;66(3):589-600 [1651174.001]
  • [Cites] Science. 1991 Aug 9;253(5020):665-9 [1651563.001]
  • [Cites] Nature. 1992 Sep 17;359(6392):235-7 [1528264.001]
  • [Cites] N Engl J Med. 1993 May 6;328(18):1313-6 [8385741.001]
  • [Cites] Am J Hum Genet. 1993 Jul;53(1):33-45 [8317496.001]
  • (PMID = 19822006.001).
  • [ISSN] 1750-1172
  • [Journal-full-title] Orphanet journal of rare diseases
  • [ISO-abbreviation] Orphanet J Rare Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 114
  • [Other-IDs] NLM/ PMC2772987
  •  go-up   go-down


17. Cascón Fonseca LF, Guerrero Gallego J, Balongo de la Vega A: [Three cases of villous adenoma of the Vater papilla]. Gastroenterol Hepatol; 2000 Apr;23(4):174-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Three cases of villous adenoma of the Vater papilla].
  • [Transliterated title] Tres casos de adenoma velloso de papila de Vater.
  • A series of three cases of villous adenoma of the papilla of Vater is reported.
  • In two cases, the pathological diagnosis made before, during and after surgery was of benign villous adenoma.
  • In the third case, the diagnosis made before and during surgery was of adenoma but in the postsurgical examination a macro-invading carcinoma was found.
  • Further endoscopic exploration revealed a recurrent villous adenoma and further surgery was carried out.
  • Total resection, rather than a duodenopancreatectomy, was performed due to the length of time from detection of the recurrence until the second operation as well as to the small size of the recurrent tumor in the surgical examination.
  • [MeSH-major] Adenoma, Villous / pathology. Ampulla of Vater. Common Bile Duct Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10863858.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] SPAIN
  •  go-up   go-down






Advertisement